Objectives: The differences in outcomes between emergent axillaryfemoral bypasses and elective axillary-femoral bypasses are not welldefined. This study compares the outcomes of emergent and elective axillary-femoral bypasses and determines the predictors of mortality for Emergent axillary-femoral bypasses.
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Serious Complications From Embolosclerotherapy of Upper Extremity High-and Low-Flow Vascular Malformations From a Specialist Single Center
Nicholas Evans, Chung S. Lim, Anthie Papadopoulou, Janice Tsui, George Hamilton, Jocelyn A. S. Brookes. Royal Free Hospital, London, United Kingdom
Objectives: Minimally invasive, embolosclerotherapy (EST) for upper extremity vascular malformations (VMs) carries significant risk of serious complications, such as ischemia, infarction, amputation, nerve injury, contracture, and ulceration, with as high as 61% rates for hand treatments most recently reported. Despite improved care in specialist centers, up-to-date estimates of complication risk for audit and informed consent are scarce; recent literature focuses on high-flow VMs (HFVM) with a paucity of data for low-flow VMs (LFVM). This study reviews the 5-year serious complications following EST of all upper extremity VM in our tertiary referral center for vascular anomalies.
Methods: All VM patients underwent multidisciplinary review directed intervention, and demographic, procedural, follow-up, and complication data collected prospectively in a dedicated database. Treatment Results: There were 70 patients who had a total of 150 EST procedures for upper extremity VMs (median age, 24.5 years; range, 1-73 years; 44 male, 26 female). Of these, 28 (40%) had EST for HFVM and 42 (60%) for LFVM (total 78 and 72 procedures, respectively). Most used agents were foam sclerosant (STD 3% mixed in ratio 2:8 with air), dehydrated absolute ethanol, and coils. Serious complications as follows: HFVM in five patients (17.9%) or 6.4% of total procedures; three ischemia of fingers and/or hand requiring amputation (Figs 1 and 2), and two skin ulcerations. Serious complication in LFVM occurred in five patients (11.9%) or 6.9% of total procedures: one median nerve injury causing wrist drop requiring nerve grafting and hand therapy, one hand contracture requiring tendon release, and three skin ulcerations. All ulcerations resolved without significant long-term disability. However, the nerve and tendon injuries carried degrees of long-term functional disability.
Conclusions: Current EST is relatively safe for upper extremity HFVM where our complication rate of 17.9% compares favorably with the recent literature, possibly owing to the selective use of foam versus alcohol, and improved classification and targeted treatment. For LFVM, significant complications resulted in 11.9% of patients from local toxicity after direct injection. These outcomes will direct treatment strategies to avoid local toxic complications in the hand for both HFVM and LFVM, and to informed consent.
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The Prognostic Implications of Diagnosing Frailty and Sarcopenia in Vascular Surgery Practice
Amir A. Ghaffarian, Wylie T. Foss, Brigitte K. Smith, Claire L. Griffen, Mark R. Sarfati, Larry W. Kraiss, Benjamin S. Brooke. University of Utah, Salt Lake City, Utah
Objectives: Frailty and sarcopenia are two related but independent conditions commonly diagnosed in older patients that can be used to predict an individual's ability to tolerate the stress of major vascular surgery. For surgical decision making, however, it is also important to know the prognostic implications associated with these conditions and estimate whether patients will live long enough to benefit from elective procedures. The objective of this study was to assess long-term survival among nonsurgical patients diagnosed with frailty and sarcopenia within an outpatient vascular surgery clinic setting.
Methods: We retrospectively reviewed all patients who presented to the vascular surgery clinic at a single academic hospital between December 2015 and August 2017 who did not subsequently undergo surgery. All patients underwent prospective frailty assessment during their clinic visit using the Clinical Frailty Scale. Patients who underwent an abdominal computed tomography scan within the prior 12 months were included in the analysis. A single axial CT-image at the most caudal end of the third lumbar vertebrae was assessed to measure crosssectional areas (in centimeters squared) of skeletal muscle, and sarcopenia was defined using established criteria of <52.4 cm 2 /m 2 for male and <38.5 cm 2 /m 2 for female patients. After stratifying patients by frailty and sarcopenia diagnoses, the association with all-cause mortality was analyzed using Kaplan-Meier curves and log-rank tests.
Results: A total of 248 patients were identified, of which 48 (19%) were diagnosed as frail and 98 (40%) met CT diagnostic criteria for sarcopenia. The median follow-up after CT imaging was 1.5 years (interquartile range, 1.1-2.2 years). When further stratified, 72 patients (29%) met only sarcopenia criteria, 22 (9%) met only frailty criteria, and 26 (11%) met criteria for both sarcopenia and frailty. Patients diagnosed with either sarcopenia or frailty were older (mean, 67 years vs 60 years; P < .001) and more likely to be male (57% vs 36%; P < .001) and have chronic obstructive pulmonary disease (67% vs 45%; P ¼ .013). When compared with patients without sarcopenia or frailty, long-term survival was significantly decreased for patients diagnosed with either sarcopenia or frailty (Fig; log-rank test P < .01). However, patients diagnosed with both sarcopenia and frailty were found to have the highest mortality rate at the 1-year follow-up.
Conclusions: Frailty and sarcopenia are common conditions among patients presenting to outpatient vascular surgery clinics that can be used to predict long-term patient survival. Identifying patients with both frailty and sarcopenia portends the worst survival, and should be taken into consideration when deciding whether to proceed with elective vascular surgery procedures. Objectives: Thoracoabdominal aneurysm (TAAA) extent 4 aneurysms share a common region of the visceral aorta with extents 2 and 3, with 3, extending proximally to the sixth intercostal space and two further to the left subclavian artery. We sought to determine how proximal extension affects outcome risk incrementally to the extent 4 visceral segment. Risk factor adjustment was performed to separate these effects from underlying disease and surgical risk factors.
Methods: Underlying vascular disease risk was estimated using risk factors of the National Cholesterol Education Program coronary heart disease risk equivalents. These are coronary heart disease, coronary artery disease, peripheral arterial disease, AAA, diabetes mellitus, and chronic kidney disease. We identified further risk factors empirically with regression methods. Aggregate risk equivalent was compared between extents by one-way analysis of variance.
Results: Between 1991 and 2017, we performed 879 repairs with TAAA extents involving the visceral segment with extent 2 (n ¼ 329), 3 (n ¼ 196), or 4 (n ¼ 354) disease. The mean age was 66 6 15 years and 35% were women (309/879). Among the vascular disease risk-equivalent factors, TAAA extent 4 had significantly higher prior AAA (27% vs 14% vs 21%; P < .0001), chronic kidney disease (P < .0007), diabetes mellitus (P < .0001), PVD (P < .003) and coronary artery disease (P < .0001) compared with TAAA extent 2 and TAAA extent 3. Vascular disease risk burden was greatest in TAAA extent 4, intermediate in TAAA extent 3, and least in TAAA extent 2, with mean scores of 1.77, 1.49, and 1.01, respectively (analysis of variance P < .0001; all pairwise comparisons P < .05). 
